Zolgensma

Made by Novartis Gene Therapies, INC. (Fka Avexis, INC.), Novartis Pharmaceuticals Corporation, Novartis Pharma Ag and Novartis Gene Therapies, INC. (Fka Avexis, INC.). Companies reported $409K in payments associated with Zolgensma to 215 clinicians (2023-2025).

See the full picture for Zolgensma · Choose a different medication

Now, who is your doctor?

We don't store what you type here. Searches stay private, and no account is needed.

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.